Título: | The effect of statins on cardiovascular outcomes by smoking status: A systematic review and meta-analysis of randomized controlled trials |
Autores: | Ursoniu, Sorin ; Mikhailidis, Dimitri P. ; Serban, Maria-Corina ; Penson, Peter ; Toth, Peter P. ; Ridker, Paul M. ; Ray, Kausik K. ; Kees Hovingh, G. ; Kastelein, John J. ; Hernandez, Adrian V. ; Manson, JoAnn E. ; Rysz, Jacek ; Banach, Maciej |
Tipo de documento: | texto impreso |
Editorial: | Academic Press, 2017-10-22T17:40:31Z |
Dimensiones: | application/pdf |
Nota general: | info:eu-repo/semantics/restrictedAccess |
Idiomas: | Inglés |
Palabras clave: | Facultad de Ciencias de la Salud , Pregrado , Artículos científicos , Medicina |
Resumen: |
El texto completo de este trabajo no está disponible en el Repositorio Académico UPC por restricciones de la casa editorial donde ha sido publicado. El texto completo de este trabajo no está disponible en el Repositorio Académico UPC por restricciones de la casa editorial donde ha sido publicado. Smoking is an important risk factor for cardiovascular disease (CVD) morbidity and mortality. The impact of statin therapy on CVD risk by smoking status has not been fully investigated. Therefore we assessed the impact of statin therapy on CVD outcomes by smoking status through a systematic review of the literature and meta-analysis of available randomized controlled trials (RCTs). The literature search included EMBASE, ProQuest, CINAHL and PUBMED databases to 30 January 2016 to identify RCTs that investigated the effect of statin therapy on cumulative incidence of major CVD endpoints (e.g. non-fatal myocardial infarction, revascularization, unstable angina, and stroke). Relative risks (RR) ratios were calculated from the number of events in different treatment groups for both smokers and non-smokers. Finally 11 trials with 89,604 individuals were included. The number of smokers and non-smokers in the statin groups of the analyzed studies was 8826 and 36,090, respectively. The RR for major CV events was 0.73 (95% confidence interval [CI]: 0.67–0.81; p Revisión por pares |
En línea: | The effect of statins on cardiovascular outcomes by smoking status: A systematic review and meta-analysis of randomized controlled trials 2017, 122:105 Pharmacological Research |
Ejemplares
Estado |
---|
ningún ejemplar |